Dynamic Assessment of Myocardial Involvement in Patients with End-Stage Renal Disease by Ultrasonic Tissue Characterization and Serum Markers of Collagen Metabolism

Clinical Cardiology

Volumn 27, Issue 4, 2004, Pages 228-234

  Fatema, Kaniz ^a   Hirono, Osamu ^a   Masakane, Ikuto ^b   Nitobe, Joji ^a   Kaneko, Kazuyoshi ^a   Zhang, Xuehua ^a   Takeishi, Yasuchika ^a   Kubota, Isao ^a  

^a YAMAGATA UNIVERSITY   (Japan)

^b Yabuki Hospital   (Japan)

Author keywords

End stage renal disease; Essential hypertension; Hemodialysis; Left ventricular hypertrophy; Matrix metalloproteinase; Tissue inhibitor of metalloproteinase; Ultrasonic integrated backscatter

Indexed keywords

COLLAGEN TYPE 1; INTERSTITIAL COLLAGENASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COLLAGEN DEGRADATION; COLLAGEN METABOLISM; CONTROLLED STUDY; DISEASE MARKER; ENZYME BLOOD LEVEL; ESSENTIAL HYPERTENSION; FEMALE; GLOMERULUS FILTRATION RATE; HEART LEFT VENTRICLE FILLING; HEART LEFT VENTRICLE MASS; HEART MUSCLE; HEART MUSCLE FIBROSIS; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE SEPTUM; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; MALE; NON INVASIVE MEASUREMENT; TISSUE CHARACTERIZATION; TREATMENT OUTCOME; ULTRASOUND;

EID: 1842426742     PISSN: 01609289     EISSN: None     Source Type: Journal    
DOI: 10.1002/clc.4960270412     Document Type: Article

References (47)

1. Hamett JD, Foley RN, Kent GM, Barre PE, Murray D, Parfrey PS: Congestive heart failure in dialysis patients: Prevalence, incidence, prognosis and risk factors. Kidney Int 1995;47:884-890
2. Dyadyk OI, Bagriy AE, Yarovaya NF: Disorders of left ventricular structure and function in chronic uremia: How often, why and what to do with it? Eur J Heart Fail 1999;1:327-336
3. Cannella G, Paoletti E, Ravera G, Cassottana P, Araghi P, Mulas D, Peloso G, Delfino R, Messa P: Inadequate diagnosis and therapy of arterial hypertension as causes of left ventricular hypertrophy in uremic dialysis patients. Kidney Int 2000;58:260-268
4. Neves PL, Silva AP, Bernardo I: Elderly patients in chronic hemodialysis: Risk factors for left ventricular hypertrophy. Am J Kidney Dis 1997;30: 224-228
5. Takiuchi S, Ito H, Iwakura K, Taniyama Y, Nishikawa N, Masuyama T, Hori M, Higashino Y, Fujii K, Minamino T: Ultrasonic tissue characterization predicts myocardial viability in early stage of reperfused acute myocardial infarction. Circulation 1998;97:356-362
6. Masuyama T, St Goar FG, Tye TL, Oppenheim G, Schnittger I, Popp RL: Ultrasonic tissue characterization of human hypertrophied hearts in vivo with cardiac cycle-dependent variation in integrated backscatter. Circulation 1989;80:925-934
7. Goens MB, Martin GR: Acoustic quantification: A new tool for diagnostic echocardiography. Curr Opin Cardiol 1996;11:52-60
8. Funck RC, Wilke A, Rupp H, Brilla CG: Regulation and role of myocardial collagen matrix remodeling in hypertensive heart disease. Adv Exp Med Biol 1997;432:35-44
9. Seccia TM, Bettini E, Vulpis V, Quartaroli M, Trist DG, Gaviraghi G, Pirrelli A: Extracellular matrix gene expression in the left ventricular tissue of spontaneously hypertensive rats. Blood Press 1999;8:57-64
10. Rossi MA: Pathologic fibrosis and connective tissue matrix in left ventricular hypertrophy due to chronic arterial hypertension in humans. J Hypertens 1998;16:1031-1041
11. Diez J, Laviades C, Mayor G, Gil MJ, Monreal I: Increased serum concentrations of procollagen peptides in essential hypertension. Relation to cardiac alterations. Circulation 1995;91:1450-1456
12. Weber KT, Janicki JS, Shroff SG, Pick R, Chen RM, Bashey RI: Collagen remodeling of the pressure-overloaded, hypertrophied nonhuman primate myocardium. Circ Res 1988;62:757-765
13. Diez J, Laviades C, Varo N, Querejeta R, Lopez B: Biochemical diagnosis of hypertensive myocardial fibrosis. Rev Esp Cardiol 2000;53(suppl 1): 8-13
14. Mukherjee D, Sen S: Alteration of cardiac collagen phenotypes in hypertensive hypertrophy: Role of blood pressure. J Mol Cell Cardiol 1993;25: 185-196
15. Laviades C, Varo N, Fernandez J, Mayor G, Gil MJ, Monreal I, Diez J: Abnormalities of the extracellular degradation of collagen type I in essential hypertension. Circulation 1998;98:535-540
16. Roten L, Nemoto S, Simsic J, Coker ML, Rao V, Baicu S, Defreyte G, Soloway PJ, Zile MR, Spinale FG: Effects of gene deletion of the tissue inhibitor of the matrix metalloproteinase-type I (TIMP-I) on left ventricular geometry and function in mice. J Mol Cell Cardiol 2000;32:109-120
17. Lindsay MM, Maxwell P, Dunn FG: TIMP-I: A marker of left ventricular diastolic dysfunction and fibrosis in hypertension. Hypertension 2002;40: 136-141
18. The sixth report of the Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. NIH publication 1997; No.98-4080
19. World Health Organization: Hypertension control. Report of a WHO expert committee. Geneva, Switzerland: World Health Organization, 1996
20. Appleton CP, Hatle LK, Popp RL: Relation of transmitral flow velocity patterns to left ventricular diastolic function: New insights from a combined hemodynamic and Doppler echocardiographic study. J Am Coll Cardiol 1988;12:426-440
21. Devereux RB, Reichek N: Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method. Circulation 1977;55: 613-618
22. Geiser EA, Bove KE: Calculation of left ventricular mass and relative wall thickness. Arch Pathol 1974;97:13-21
23. Fujimoto N, Iwata K: Enzyme immunoassays for matrix metalloproteinases and their inhibitors. Connective Tissue 1994;26:237-244
24. Zhang J, Fujimoto N, Iwata K, Sakai T, Okada Y, Hayakawa T: A one-step sandwich enzyme immunoassay for human matrix metalloproteinase I (interstitial collagenase) using monoclonal antibodies. Clin Chim Acta 1993; 219:1-14
25. Kodama S, Iwata K, Iwata H, Yamashita K, Hayakawa T: Rapid one-step sandwich enzyme immunoassay for tissue inhibitor of metalloproteinases. An application for rheumatoid arthritis serum and plasma. J Immunol Meth 1990;127:103-108
26. National Kidney Foundation: K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification and stratification. Am J Kidney Dis 2002(suppl 1);39:S77-S92
27. Gotch FA, Sargent JA: A mechanistic analysis of the National Cooperative Dialysis Study (NCDS). Kidney Int 1985;28:526-534
28. London GM, Guerin AP, Marchais SJ: Pressure-overload cardiomyopathy in end-stage renal disease. Curr Opin Nephrol Hypertens 1999;8:179-186
29. Ansai A, Kaupke CJ, Vaziri ND, Miller R, Barbari A: Cardiac pathology in patients with end-stage renal disease maintained on hemodialysis. IntJArtif Organs 1993;16:31-36
30. Mall G, Rambausek M, Gretz N, Ikker U, Zimmer G, Klingel K, Schneider J, Jansen HH, Ritz E: Interstitial myocardial fibrosis in chronic uremia-the cause of chronic diastolic malfunction in dialysis patients? Pathologe 1989; 10:200-205
31. Foley RN, Parfrey PS, Kent GM, Harnett JD, Murray DC, Barre PE: Serial change in echocardiographic parameters and cardiac failure in end-stage renal disease. J Am Soc Nephrol 2000;11:912-916
32. Ganau A, Devereux RB, Roman MJ, de Simone G, Pickering TG, Saba PS, Vargiu P, Simongini I, Laragh JH: Patterns of left ventricular hypertrophy and geometric remodeling in essential hypertension. J Am Coll Cardiol 1992;19:1550-1558
33. Mizushige K, Tokudome T, Seki M, Kondo I, Hirao K, Nozaki S, Miki S, Yuasa S, Matsuo H: Sensitive detection of myocardial contraction abnormality in chronic hemodialysis patients by ultrasonic tissue characterization with integrated backscatter. Angiology 2000;51:223-230
34. Dollery CM, McEwan JR, Henney AM: Matrix metalloproteinases and cardiovascular disease. Circ Res 1995;77:863-868
35. Robert V, Besse S, Sabri A, Silvestre JS, Assayag P, Nguyen VT, Swynghedauw B, Delcayre C: Differential regulation of matrix metalloproteinases associated with aging and hypertension in the rat heart. Lab Invest 1997;76: 729-738
36. Manicourt DH, Fujimoto N, Obata K, Thonar EJ: Serum levels of collagenase, stromelysin-I, and TIMP-I. Age- and sex-related differences in normal subjects and relationship to the extent of joint involvement and serum levels of antigenic keratan sulfate in patients with osteoarthritis. Arthritis Rheum 1994;37:1774-1783
37. Border WA, Noble NA: Transforming growth factor beta in tissue fibrosis. N Engl J Med 1994;331:1286-1292
38. Edwards DR, Murphy G, Reynolds JJ, Whitham SE, Docherty AJ, Angel P, Heath JK: Transforming growth factor beta modulates the expression of collagenase and metalloproteinase inhibitor. Eur Molec Biol Org J 1987;6: 1899-1904
39. Porreca E, Di Febbo C, Mincione G, Reale M, Baccante G, Guglielmi MD, Cuccurullo F, Colletta G: Increased transforming growth factor-beta production and gene expression by peripheral blood monocytes of hypertensive patients. Hypertension 1997;30:134-139
40. Brilla CG, Reams GP, Maisch B, Weber KT: Renin-angiotensin system and myocardial fibrosis in hypertension: Regulation of the myocardial collagen matrix. Eur Heart J 1993;14:57-61
41. Brilla CG, Maisch B, Weber KT: Renin-angiotensin system and myocardial collagen matrix remodeling in hypertensive heart disease: In vivo and in vitro studies on collagen matrix regulation. Clin Invest 1993;71:S35-41
42. Lopez B, Querejeta R, Varo N, Gonzalez A, Larman M, Martinez Ubago JL, Diez J: Usefulness of serum carboxy-terminal propeptide of procollagen type 1 is assessment of the cardioreparative ability of antihypertensive treatment in hypertensive patients. Circulation 2001;104:286-291
43. Querejeta R, Varo N, Lopez B, Larman M, Artinano E, Etayo JC, Martinez Ubago JL, Gutierrez-Stampa M, Emparanza JI, Gil MJ, Monreal I, Mindan JP, Diez J: Serum carboxy-terminal propeptide of procollagen type I is a marker of myocardial fibrosis in hypertensive heart disease. Circulation 2000;101:1729-1735
44. O'Brien WD, Sagar KB, Warltier DC, Rhyne TL: Acoustic propagation properties of normal, stunned, and infarcted myocardium. Morphological and biochemical determinants. Circulation 1995;91:154-160
45. Chandrasekaran K, Bansal RC, Greenleaf JF, Hauck A, Seward JB, Tajik AJ, Bailey LL: Early recognition of heart transplant rejection by backscatter analysis from serial 2D Echos in a heterotopic transplant model. J Heart Transplant 1987;6:1-7
46. Wu SG, Lin SL, Wu CM, Jeng FR, Su CZ: Optimal control of blood pressure can reverse left ventricular hypertrophy in uremic hypertensive hemodialysis patients. Kaohsiung J Med Sci 1999;15:62-68
47. Conion PJ, Walshe JJ, Heinle SK, Minda S, Krucoff M, Schwab SJ: Predialysis systolic blood pressure correlates strongly with mean 24-hour systolic blood pressure and left ventricular mass in stable hemodialysis patients. J Am Soc Nephrol 1996;7:2658-2663